Latvia
2.7researchedThe ownership rule is more permissive than it looks, and the detail is the word "or". Article 36(2) of the Farmācijas likums is satisfied either by a pharmacist holding half the shares **or** by pharmacists making up half the board, which means a corporate group can comply with no pharmacist equity at all. Everything else is closed: prescription mail order is unlawful, obesity is not a reimbursable diagnosis in any form, and the reimbursed diabetes route carries a hard stopping rule.
- Population
- 1.85m
- Currency
- EUR
- Region
- Baltic Europe
- Updated
- 2026-08-24
The six axes
Five is always better for an operator. Hover a label for the question it answers.
How it works here
The word that changes the ownership answer [1]
Article 36(2) of the Farmācijas likums provides that a pharmacy may operate as a capital company if at least one of the following conditions is met: not less than 50% of the company’s shares belong to a pharmacist, or not less than half of the members of the company’s board are certified pharmacists.
The phrase is vismaz viens no šādiem nosacījumiem, at least one of the following. These are alternatives. A corporate group can therefore comply through board composition alone, with no pharmacist holding any equity at all. That is a materially different proposition from a pharmacist-majority ownership rule, and it is the single most commercially important nuance in Latvian pharmacy law.
Article 36(1) permits three vehicles: a pharmacist’s practice, a joint practice, or a capital company. Where a pharmacy belongs to a municipality or a non-pharmacist, an employment contract with a certified pharmacist must be concluded. Article 36(3) allows a pharmacist’s assistant to establish a pharmacy in a locality under 4,000 people with no other pharmacy within 5 km, on a five-year licence.
The article has been stable since 1 January 2011. The Act was amended in June 2024 and again on 30 April 2026, in force 29 May 2026, but neither touched article 36. No statutory cap on the number of pharmacies was found; control operates through Cabinet siting criteria instead.
Mail order is over-the-counter only, but the delivery layer is unusual [1]
The Zāļu valsts aģentūra states plainly that Latvian law permits distribution via a website of non-prescription medicines only, that only a general or open-type pharmacy holding a licence whose annex carries the specific special-activity condition may do it, and that only products entered in the Latvian Medicines Register may be sold, because classification differs between member states. The governing instruments are Cabinet Regulation No. 410 of 1 June 2025 on pharmaceutical activity licensing and Cabinet Regulation No. 416 of 26 June 2007 on distribution and quality control.
What is distinctive is who appears on the register. Alongside the expected pharmacy websites, Apotheka, InternetAptieka.lv, benu.lv, euroaptieka.lv and others, AS Sentor Farm Aptiekas appears repeatedly through delivery platforms: Wolt Latvija SIA, Bolt Services LV SIA and Bolt Operations OÜ. BENU also lists via Wolt. Latvia has a genuinely platform-intermediated pharmacy delivery market.
A GLP-1 operator cannot use any of it. The channel is real, it is regulated, and it is closed to prescription medicines.
Cross-border e-prescription: ten countries, not nine [1][2]
Latvia is one of the states that will dispense an Estonian digiretsept, and the Estonian health fund’s own page lists ten recipients rather than the nine this atlas previously recorded: Finland, Croatia, Portugal, Poland, Spain, Greece, Cyprus, Lithuania, Latvia and Czechia. The Estonia page has been corrected accordingly.
From the Latvian side, e-veselība reports exchange with Lithuania, Estonia, Poland, Czechia and part of Spain, with Finland, Croatia and Cyprus added during 2026, and bidirectional exchange with Greece from 10 August 2026 including patient summaries. Latvians have been able to use Latvian e-prescriptions elsewhere in the EU since March 2024.
The volumes put the mechanism in perspective. In the first half of 2026 Latvia issued over 9 million e-prescriptions domestically. Cross-border use was 1,309 Latvian prescriptions dispensed abroad and 794 foreign prescriptions dispensed in Latvia. The infrastructure works; it is being used by travellers, not as a distribution channel.
Reimbursement: nothing for obesity, and a stopping rule for diabetes [1][2]
Obesity is not a reimbursable diagnosis in Latvia at all. The compensated-diagnosis list in force from 1 July 2026 contains no ICD-10 E66 row and no reference to aptaukošanās, and Wegovy, Saxenda and tirzepatide appear nowhere on the A or B lists.
Semaglutide is reimbursed for type 2 and other specified diabetes, on the B list, under conditions worth reading in full because they cap persistence directly. Prescribing is limited to an endocrinologist, cardiologist or family doctor. Eligibility requires either BMI at or above 30 in combination with metformin where triple therapy has failed to hold HbA1c below 7%, or documented cardiovascular disease. And then: therapy must be discontinued if within six months HbA1c has not fallen by at least 1% and/or weight by at least 3%.
A mandatory stopping rule tied to response is unusual and it changes the shape of the reimbursed cohort. It also, indirectly, feeds the self-pay market, because a patient discontinued under the rule who wants to continue has only one route.
One unresolved tension: the diagnosis list shows compensation at 100% for E11 and E13, while the price file’s column heading reads 75%. Do not quote a Latvian patient co-pay without closing that point.
Verified self-pay prices [1]
The Latvian Medicines Register open data, current to 24 August 2026, gives prices including VAT. All GLP-1 products carry prescription-only legal status.
- Wegovy 0.25, 0.5 and 1 mg: 145.92 euros. 1.7 mg: 166.92 euros. 2.4 mg: 192.20 euros.
- Mounjaro 2.5 mg: 177.03 euros. 5 mg: 240.41 euros. 7.5 and 10 mg: 335.41 euros. 12.5 and 15 mg: 430.44 euros.
- Ozempic 0.25, 0.5 and 1 mg: 109.24 euros. 2 mg: 217.48 euros.
Because obesity is unreimbursed, the Wegovy and Mounjaro figures are what a Latvian patient pays. A handful of register entries carry much higher values, Wegovy 2.4 mg at 1,156.33 euros for instance, which are most likely multi-pen or parallel-import presentations and should not be read as unit prices.
Also registered but unpriced: oral Wegovy tablet strengths of 4, 9 and 25 mg, and a Wegovy 7.2 mg pen. Registration ahead of launch.
Who is already there
| Name | Model | Price |
|---|---|---|
| Apotheka | Largest Latvian pharmacy network, licensed for online OTC sale | n/a |
| BENU Aptieka Latvija | Phoenix group chain, listed both directly and through Wolt | n/a |
| AS Sentor Farm Aptiekas | Mēness aptieka and related brands; reaches the online OTC register through Wolt and Bolt rather than its own storefront | n/a |
| Wolt Latvija, Bolt Services LV | Delivery platforms carrying licensed OTC pharmacy storefronts, an unusual structure for the EU | n/a |
Routes in, and walls
What works viable
- Satisfy article 36(2) through board composition rather than shareholding. Half the board being certified pharmacists requires no pharmacist equity.
- Serve the cohort discontinued under the six-month HbA1c and weight stopping rule, which is a defined, identifiable self-pay population.
- Price against the verified register figures rather than guessing; Latvia is one of the few markets where official self-pay prices are readable.
What does not blocked
- Selling prescription medicines online. The regulator states the permission covers non-prescription only.
- Advertising prescription GLP-1s to the Latvian public, or offering them at a discount, which Cabinet Regulation 378 bars separately.
- Treating cross-border e-prescription volumes as a distribution channel. 794 inbound prescriptions in six months is travel, not trade.
How to make it work
The recommended entry path for a non-pharmacist operator running an own brand with a partner pharmacy. Read it against the six axes above, not instead of them.
Satisfy the board-composition rule rather than buying pharmacist equity, and serve the cohort the stopping rule discontinues.
Article 36(2) can be satisfied through board composition rather than shareholding, so half the board being certified pharmacists requires no pharmacist equity. That is a genuinely useful structural detail. And Latvia has a defined, identifiable self-pay population: patients discontinued under the six-month HbA1c and weight stopping rule.
- Structure the board rather than the cap tableHalf the board certified, no pharmacist shareholding required.
- Target the discontinued cohortThe stopping rule creates a defined population with a clear need and no route.
- Price against the published register figuresLatvia is one of the few markets where official self-pay prices are readable.
Very small market, and mail order scores 1 out of 5.
Low.
What has happened
What we could not establish
Kept visible on purpose. These are the gaps a decision would have to close.
- Is diabetes semaglutide reimbursed at 100% or 75%? The diagnosis list and the price file disagree.
- Does Latvian law permit prescribing after an online-only consultation? The prescription regulation is silent, neither authorising nor prohibiting it.
- Has the Veselības inspekcija taken any GLP-1 advertising enforcement action?
- What are the high-value register entries, for instance Wegovy 2.4 mg at 1,156 euros? Multi-pen packs, parallel imports, or an artefact?
Sources
Every non-obvious claim above links here. Confidence tags are applied strictly.